SG11201811745UA - T cell compositions for immunotherapy - Google Patents
T cell compositions for immunotherapyInfo
- Publication number
- SG11201811745UA SG11201811745UA SG11201811745UA SG11201811745UA SG11201811745UA SG 11201811745U A SG11201811745U A SG 11201811745UA SG 11201811745U A SG11201811745U A SG 11201811745UA SG 11201811745U A SG11201811745U A SG 11201811745UA SG 11201811745U A SG11201811745U A SG 11201811745UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- june
- pct
- immunotherapy
- cell compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 3
- 238000009169 immunotherapy Methods 0.000 title abstract 3
- 108010002350 Interleukin-2 Proteins 0.000 abstract 5
- 108700012920 TNF Proteins 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000012099 Alexa Fluor family Substances 0.000 abstract 1
- 101710145634 Antigen 1 Proteins 0.000 abstract 1
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 abstract 1
- 101150106931 IFNG gene Proteins 0.000 abstract 1
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 abstract 1
- 102000003729 Neprilysin Human genes 0.000 abstract 1
- 108090000028 Neprilysin Proteins 0.000 abstract 1
- 241000656145 Thyrsites atun Species 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000004172 quinoline yellow Substances 0.000 abstract 1
- 230000009257 reactivity Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4201—Neoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662355506P | 2016-06-28 | 2016-06-28 | |
| US201662355533P | 2016-06-28 | 2016-06-28 | |
| US201662355458P | 2016-06-28 | 2016-06-28 | |
| PCT/US2017/039846 WO2018005712A1 (fr) | 2016-06-28 | 2017-06-28 | Compositions de lymphocytes t pour immunothérapie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201811745UA true SG11201811745UA (en) | 2019-01-30 |
Family
ID=60787739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201811745UA SG11201811745UA (en) | 2016-06-28 | 2017-06-28 | T cell compositions for immunotherapy |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20200237819A1 (fr) |
| EP (1) | EP3487990A4 (fr) |
| JP (3) | JP7034955B2 (fr) |
| KR (1) | KR20190037243A (fr) |
| CN (1) | CN109715788A (fr) |
| AU (2) | AU2017290119A1 (fr) |
| CA (1) | CA3068387A1 (fr) |
| IL (1) | IL263896A (fr) |
| MX (1) | MX2019000180A (fr) |
| SG (1) | SG11201811745UA (fr) |
| WO (1) | WO2018005712A1 (fr) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2812431T3 (da) | 2012-02-09 | 2019-10-14 | Baylor College Medicine | Peptidblandinger til generering af multivirale ctl'er med bred specificitet |
| KR101413519B1 (ko) | 2013-05-15 | 2014-07-02 | 전태화 | 휴즈의 리드선 절단 및 절곡장치 |
| BR112017020058A2 (pt) * | 2015-03-20 | 2018-06-05 | Childrens Nat Medical Ct | processo para produzir uma célula-t específica, composição, banco de células-t específicas, método de tratamento, e, banco ou instalação de armazenamento de células. |
| SI3532607T1 (sl) | 2016-10-26 | 2024-06-28 | Iovance Biotherapeutics, Inc. | Restimulacija limfocitov, ki infiltrirajo kriokonzervirani tumor |
| TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
| WO2018094167A1 (fr) | 2016-11-17 | 2018-05-24 | Iovance Biotherapeutics, Inc. | Lymphocytes infiltrant les tumeurs restantes et leurs procédés de préparation et d'utilisation |
| JP2020503351A (ja) | 2017-01-06 | 2020-01-30 | アイオバンス バイオセラピューティクス，インコーポレイテッド | カリウムチャネルアゴニストによる腫瘍浸潤リンパ球の増殖及びその治療的使用 |
| WO2018135646A1 (fr) | 2017-01-20 | 2018-07-26 | 国立大学法人京都大学 | PROCÉDÉ DE PRODUCTION DE LYMPHOCYTES T CD8α+β+ CYTOTOXIQUES |
| US11254913B1 (en) | 2017-03-29 | 2022-02-22 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| US11793867B2 (en) * | 2017-12-18 | 2023-10-24 | Biontech Us Inc. | Neoantigens and uses thereof |
| AU2019205823A1 (en) | 2018-01-08 | 2020-07-30 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
| JP7198602B2 (ja) * | 2018-07-11 | 2023-01-04 | カワサキモータース株式会社 | 自動二輪車 |
| AU2019314888A1 (en) * | 2018-07-31 | 2021-02-18 | Polybiocept Gmbh | Production and selection of tumor uber reactive immune cells (TURICs) |
| CN112513255A (zh) * | 2018-07-31 | 2021-03-16 | 赛雅思株式会社 | 介由iPS细胞制造再生T细胞群体的方法 |
| WO2020032780A1 (fr) * | 2018-08-10 | 2020-02-13 | 주식회사 유틸렉스 | Cellules t cytotoxiques spécifiques d'un antigène tumoral |
| KR20210042142A (ko) * | 2018-08-10 | 2021-04-16 | 주식회사 유틸렉스 | 암항원 특이적 cd8+ t 세포의 제조 및 동결보존 방법 |
| WO2020102701A1 (fr) * | 2018-11-16 | 2020-05-22 | Rapa Therapeutics, Llc | Procédés de fabrication de lymphocytes t de phénotype th1/tc1 |
| MX2021007353A (es) * | 2018-12-18 | 2021-11-17 | Beth Israel Deaconess Medical Ct Inc | Generación de células t sensibilizadas por organoide (opt) con fenotipo de memoria. |
| US20220064598A1 (en) * | 2019-01-07 | 2022-03-03 | Children's National Medical Center | Ex vivo activated t-lymphocytic compositions and methods of using the same |
| US20220128564A1 (en) * | 2019-02-14 | 2022-04-28 | Research Institute At Nationwide Children's Hospital | Use of a stimulating agent to assay immune cell potency |
| WO2020243729A1 (fr) * | 2019-05-31 | 2020-12-03 | Children's National Medical Center | Cocktails de cytokines pour expansion sélective de sous-ensembles de lymphocytes t |
| JP7337373B2 (ja) * | 2019-07-29 | 2023-09-04 | サイアス株式会社 | 抗原特異的ｔ細胞の製造方法 |
| CN114615886A (zh) * | 2019-08-29 | 2022-06-10 | 得克萨斯大学体系董事会 | 细胞冷冻保存培养基 |
| EP4065229A1 (fr) * | 2019-11-27 | 2022-10-05 | Myst Therapeutics, LLC | Procédé de production d'une composition de lymphocytes t réactifs à une tumeur faisant appel à des agents modulateurs |
| EP4251177A4 (fr) * | 2020-11-25 | 2025-01-08 | Geneius Biotechnology Inc | Lymphocytes t spécifiques d'un antigène et méthodes de fabrication et d'utilisation associées |
| CN113481157B (zh) * | 2021-07-21 | 2023-03-17 | 上海赛傲生物技术有限公司 | 特异性抗病毒过继免疫细胞的优化制备方法 |
| CN113564116B (zh) * | 2021-07-21 | 2023-08-01 | 北京赛傲生物技术有限公司 | 特异性抗病毒过继免疫细胞ce的制备方法 |
| CN113512529B (zh) * | 2021-07-21 | 2022-11-25 | 上海赛傲生物技术有限公司 | 特异性抗病毒过继免疫细胞ab的制备方法 |
| IL310696A (en) * | 2021-09-08 | 2024-04-01 | Ksq Therapeutics Inc | Lymphocyte potency assay |
| WO2023060195A1 (fr) * | 2021-10-08 | 2023-04-13 | Baylor College Of Medicine | Ciblage de mutations somatiques communes dans le cancer du sein avec une thérapie cellulaire adoptive par lymphocytes t spécifique de néo-antigène |
| JP2023064787A (ja) * | 2021-10-27 | 2023-05-12 | 国立大学法人京都大学 | Ｔ細胞の品質評価方法、および当該方法に用いる試薬 |
| WO2023178140A2 (fr) * | 2022-03-18 | 2023-09-21 | St. Jude Children's Research Hospital, Inc. | Méthode de préparation de lymphocytes t pour thérapie adoptive par lymphocytes t |
| WO2023201369A1 (fr) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | Processus d'expansion de til utilisant des combinaisons spécifiques de cytokine et/ou traitement akti |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999058977A1 (fr) * | 1998-05-11 | 1999-11-18 | Miltenyi Biotec Gmbh | Methode de selection directe de cellules t antigenes-specifiques |
| EP2363710B1 (fr) * | 2002-08-08 | 2015-07-01 | Baylor College Of Medicine | Isolement et identification des t-cellules |
| HUE024541T2 (hu) * | 2008-05-14 | 2016-01-28 | Immatics Biotechnologies Gmbh | Szurvivinbõl és neurocanból származó új és hatásos II-es osztályú MHC peptidek |
| US9963677B2 (en) * | 2009-08-24 | 2018-05-08 | Baylor College Of Medicine | Generation of CTL lines with specificity against multiple tumor antigens or multiple viruses |
| WO2011146473A1 (fr) * | 2010-05-17 | 2011-11-24 | Duke University | Procédés de traitement à l'aide de l'expansion in vivo de lymphocytes t du sang du cordon ombilical |
| KR20160104753A (ko) * | 2011-05-26 | 2016-09-05 | 지니우스 바이오테크놀로지 인베스트먼트, 엘엘씨 | 조절된 면역우세 요법 |
| US10316289B2 (en) | 2012-09-06 | 2019-06-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing T memory stem cell populations |
| JP6998763B2 (ja) * | 2014-09-04 | 2022-02-04 | ステムセル テクノロジーズ インコーポレーティッド | Ｔ細胞またはｎｋ細胞を活性化および増加させるための、可溶性抗体複合体 |
-
2017
- 2017-06-28 AU AU2017290119A patent/AU2017290119A1/en not_active Abandoned
- 2017-06-28 CN CN201780053540.8A patent/CN109715788A/zh active Pending
- 2017-06-28 MX MX2019000180A patent/MX2019000180A/es unknown
- 2017-06-28 KR KR1020197002828A patent/KR20190037243A/ko not_active Application Discontinuation
- 2017-06-28 CA CA3068387A patent/CA3068387A1/fr active Pending
- 2017-06-28 EP EP17821200.7A patent/EP3487990A4/fr active Pending
- 2017-06-28 WO PCT/US2017/039846 patent/WO2018005712A1/fr unknown
- 2017-06-28 JP JP2018569009A patent/JP7034955B2/ja active Active
- 2017-06-28 SG SG11201811745UA patent/SG11201811745UA/en unknown
- 2017-06-28 US US16/312,023 patent/US20200237819A1/en not_active Abandoned
-
2018
- 2018-12-23 IL IL263896A patent/IL263896A/en unknown
-
2022
- 2022-03-02 JP JP2022031731A patent/JP2022066355A/ja active Pending
- 2022-06-16 US US17/807,213 patent/US20230145991A1/en active Pending
-
2023
- 2023-10-26 AU AU2023254998A patent/AU2023254998A1/en active Pending
-
2024
- 2024-05-22 JP JP2024083379A patent/JP2024103547A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190037243A (ko) | 2019-04-05 |
| JP2024103547A (ja) | 2024-08-01 |
| MX2019000180A (es) | 2019-11-05 |
| IL263896A (en) | 2019-01-31 |
| JP2022066355A (ja) | 2022-04-28 |
| CA3068387A1 (fr) | 2018-01-04 |
| EP3487990A1 (fr) | 2019-05-29 |
| JP7034955B2 (ja) | 2022-03-14 |
| AU2023254998A1 (en) | 2023-11-16 |
| WO2018005712A1 (fr) | 2018-01-04 |
| US20230145991A1 (en) | 2023-05-11 |
| EP3487990A4 (fr) | 2020-07-29 |
| AU2017290119A1 (en) | 2019-01-24 |
| US20200237819A1 (en) | 2020-07-30 |
| CN109715788A (zh) | 2019-05-03 |
| JP2019519246A (ja) | 2019-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811745UA (en) | T cell compositions for immunotherapy | |
| SG11201809710RA (en) | Genetically engineered cells and methods of making the same | |
| SG11201908527SA (en) | High affinity mage-a1-specific tcrs and uses thereof | |
| SG11201803701YA (en) | Methods and compositions for gene editing in hematopoietic stem cells | |
| SG11201806758VA (en) | Vcn enhancer compositions and methods of using the same | |
| SG11201805449PA (en) | Methods of making chimeric antigen receptor -expressing cells | |
| SG11201808797XA (en) | T cell receptors | |
| SG11201909652WA (en) | Neoantigen identification, manufacture, and use | |
| SG11201908337VA (en) | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells | |
| SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
| SG11201808968WA (en) | Time division multiplexing of synchronization channels | |
| SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201808783XA (en) | Cd80 variant immunomodulatory proteins and uses thereof | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201907857RA (en) | Edible and biodegradable utensils | |
| SG11201810591VA (en) | Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen | |
| SG11201408787PA (en) | Enhancing activity of car t cells by co-introducing a bispecific antibody | |
| SG11201810509PA (en) | Anti-pd-l1 antibodies | |
| SG11202000149VA (en) | Methods and apparatus for srs antenna switching in carrier aggregation | |
| SG11201804563SA (en) | Digital microfluidic system for single-cell isolation and characterization of analytes | |
| SG11201807369UA (en) | System and method for beam adjustment request | |
| SG11201908675PA (en) | Computer-implemented system and method for performing transaction mixing on a blockchain | |
| SG11201900975XA (en) | Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same | |
| SG11201901640RA (en) | Method and apparatus for reception of transmit power related information |